Table 1:
Sample characteristics
| Hodgkin Lymphoma Survivors N=197 |
Controls N=199 |
p-value1 | |
|---|---|---|---|
| N (%) | N (%) | ||
| Male | 95(48.2) | 94(47.2) | 0.84 |
| White | 167(84.8) | 171(85.9) | 0.75 |
| Smoking Status | |||
| Current | 38(19.3) | 29(14.6) | |
| Former | 33(16.8) | 42(21.1) | |
| Never | 126(64.0) | 128(64.3) | 0.32 |
| Body Mass Index (BMI) | |||
| Underweight | 7(3.6) | 2(1.0) | |
| Normal weight | 50(25.4) | 62(31.2) | |
| Overweight | 69(35.0) | 58(29.1) | |
| Obese | 71(36.0) | 77(38.7) | 0.15 |
| Recent Infection | 12 (6.1) | 14 (7.0) | 0.72 |
| Anti-Inflammatory Medication2 | 46 (23.4) | 37 (18.6) | 0.24 |
| Age at Assessment (Years) | |||
| Median (min, max) | 35.41 (22.63, 64.64) | 35.38 (18.28, 65.89) | 0.98 |
| Age at Diagnosis (Years) | |||
| Median (min, max) | 14.84 (3.01,22.60) | - | - |
| Time Since Diagnosis (Years) | |||
| Median (min, max) | 20.52 (10.68,45.62) | - | - |
| Treatment Exposures 3 | |||
| Anthracyclines (mg/m2) | 148 (75.1) | - | - |
| Median (min, max) | 157.20(91.50-400) | - | - |
| IV Methotrexate (mg/m2) | 81 (41.1) | - | - |
| Median (min, max) | 122.88(20.28-167.66) | - | - |
| Vincristine (mg/m2) | 133 (67.5) | - | - |
| Median (min, max) | 8.28(1.56-73.27) | - | - |
| Alkylating Agents (mg/m2) | 131 (66.5) | - | - |
| Median (min, max) | 6896.8(1189-28980) | - | - |
| Bleomycin (yes) | 56(28.4) | - | - |
| Prednisone (yes) | 135 (68.9) | ||
| Chest Radiation | |||
| <24 Gy | 48(24.4) | ||
| 24-30 Gy | 108(54.8) | - | - |
| >30 Gy | 41(20.8) | - | - |
| Neck Radiation | |||
| ≥30 Gy | 34(17.3) | - | - |
| 20 to <30 Gy | 143(72.6) | - | - |
| <20 Gy | 20(10.2) | - | - |
| Relapsed | 14(7.1) | - | - |
| Subsequent Malignancy4 | 40(20.3) | - | - |
Gy: Gray
1
p-value from Chi-square tests or two sided t-tests
2
anti-inflammatory medications included any non-steroidal anti-inflammatory drugs (NSAID, e.g. ibuprofen) and steroid medication
3
Mean(SD) and median (range) for all chemo and radiation doses were based on those who received treatment exposure
4
subsequent malignancies included 6 genitourinary tumors (2 uterine, 3 cervical, 1 testicular), 11 non-melanoma skin cancers, 10 thyroid tumors, 10 breast tumors, 1 lymphoma, and 2 parotid tumors.